To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia

NCT06622824 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

756

Enrollment

INDUSTRY

Sponsor class

Conditions

Androgenetic Alopecia (AGA)

Interventions

DRUG: KX-826 0.5% BID
DRUG: KX-826 1.0% BID
DRUG: Vehicle (Placebo) applied BID

Sponsor

Suzhou Kintor Pharmaceutical Inc,

Collaborators

[object Object]